Business Plan & Progress

From Science to Global Implementation

Transforming diabetes care from management to cure, with a roadmap that connects clinical proof, sustainable business, and social impact.

Updated: 2025/08/22

Business Plan & Progress

This section provides an overview of the Biozipcode Group’s overall business plan. For precise information, please refer to each individual business entity.

Auring Inc & Biozipcode Group

Global Development Token (GDT) Issuance and Sales with Operationalization.

UAE, Japan, Palau, U.S.

Legal and Governance Establishment

Redesign from the Palau Development Token (PWDT) to the Global Development Token (GDT), focusing on clinical trials in Palau, with the Biozipcode Group taking a leading role in full participation. 100%
Establish issuing entity (Auring Inc., BVI) 100%
Prepare capital and wallet management (hardware/paper wallets, etc.) 100%
Verify regulatory compliance across multiple jurisdictions (UAE, Japan, U.S.), establish KYC/AML and data protection policies 50%
Publish a White Paper for GDT 100%

Token Demand & Supply

Token Issuance and Sales

Finalize GDT token design 100%
Issue GDT tokens 100%
Conduct Seed phase sale 50%
Conduct Private phase sale 0%
Conduct Public sale (first half / second half) 0%

Social Implementation Centerd on Prof.Kojima

Integration of Token Utility

Special Medical Tours for Investor 90%
High-end medical retreats 20%
5-ALA formulations and supplements 100%
Biomarker diagnostic tests 50%
Online consultations with specialists 90%

Palau's Foreign Investment Board

Operationalization

Set prices for medical services in USD, converted into GDT for seamless payments 100%
Implement UI/accounting integration for transactions 100%
Meeting with cryptocurrency exchange regarding listing 50%
Listing of GDT tokens on cryptocurrency exchanges 0%

Palau's Foreign Investment Board

Stabilization and Transparency

Maintain zero additional issuance, immediate transparent circulation 100%
Initiate 20% burn policy on medical service payments received in GDT 0%
Publish quarterly operational reports, including balances, major expenditures, and burn status 30%

Note: As the VASP license in Palau is currently awaiting legislative approval, the stablecoin business is planned to be implemented under a separate entity in the future.

Biozipcode Inc. (Japan)

Aiming for a complete cure rather than symptomatic treatment with “a cure for diabetes” and “technology to deliver drugs to specific cells (cell targeting technology).”

Diabetes Stem Cells

Development and Commercialization of a Diabetes Cure and Diagnostic Kit (Biomarker)

Preclinical (Animal Studies)

Conduct proof-of-concept (POC) experiments to confirm efficacy 100%
Establish clinical trial protocols and organizational structures (ethics committees, regulatory pathways, clinical trial teams) 80%
Secure GMP manufacturing and supply of investigational drugs (5-ALA + HDAC inhibitor) 100%

Palau Islands from Above

Phase IIb in Palau

Finalize agreement with Belau National Hospital for clinical trial implementation 75%
Obtain approval from the Ministry of Health ethics committee in Palau 25%
Conduct public awareness campaigns in Palau regarding the clinical trial 5%
Register participants 0%
Initiate patient dosing 0%
Conduct interim analysis to reconfirm efficacy and safety 0%
Analyze results from the trial and post-trial follow-up 0%

Multi Nations

Multinational Phase III

Prepare for clinical trials in the UAE, Japan, and the United States 10%
Collect and submit data required by regulatory authorities (FDA, PMDA, etc.) 30%
Conduct Phase III trials in each country 0%
Apply for and obtain regulatory approval in each jurisdiction 0%
Perform post-marketing surveillance (Phase IV) to continuously monitor safety 0%

Biozipcode Image

Diabetes Diagnostic Kit (Biomarker)

Conduct preclinical POC studies at the laboratory level (animal studies) 100%
Perform analytical validation and develop diagnostic kits 70%
Carry out clinical trials in Palau 15%
Obtain regulatory approvals in multiple countries 0%
Begin production of diagnostic kits 0%
Launch diagnostic kits under health insurance reimbursement schemes 0%

Palau Sambas Development Inc. (Palau)

High-end tourism (retreats), SDGs-related projects, diabetes clinical trial initiatives, PWDT, (stablecoin business), and others

Palau Koror City

Operation of High-End Tourism (Retreats)

Establishing the framework for the high-end tourism business 60%
Signing MoUs with local partner companies 30%
Preparing stay-type retreat facilities 0%
Hosting high-end medical retreat tours for investor groups 0%

Belau National Hospital (Palau)

Clinical Trials for a Diabetes Cure and Related Biomarker Projects

Reviewing the overall framework of the clinical trial protocol 80%
Direct meetings with Belau National Hospital 100%
Conducting research activities related to diabetes clinical trials in Palau 20%
Preparing local initiatives such as lunch distribution programs 0%
Preparing local nutrition guidance and related activities 0%
Launching clinical trial–related projects 0%
Conducting follow-up research after the completion of each trial 0%

Palau's Foreign Investment Board

PWDT, (Stablecoin Business), SDGs-Related Projects and Others

Holding meetings with key figures in Palau 100%
Establishing a local corporation 100%
Obtaining a business license 80%

Note: As the VASP license in Palau is currently awaiting legislative approval, the stablecoin business is planned to be implemented under a separate entity in the future.

Launch of a new company under FIB registration focused on stablecoins 60%
Getting Virtual Asset Service Providers (VASP) License 10%

Note: VASP license in Palau is currently awaiting legislative approval.

Agreement & MoU

This section provides an outline of the Biozipcode Group’s key agreements and MoUs. For specific and current details, please check with each partner organization directly.

Koror States SDGs Recycling Factory

Belau National Hospital

Executed Soon

Leading investment company in the UAE
Leading business entity in the UAE
Government of Palau
Koror States Government
Belau National Hospital
Group of Japanese nutrition experts
Japanese clinics

Shiga University of Medical Science

Executed

2022

Shiga University of Medical Science & Biozipcode, Inc.
Establishment of a joint research course (through March 2025).

Biozipcode, Inc. & Senard Co., Ltd.
Business partnership for compliance checks.

Supporters of Biozipcode

2023

Biozipcode, Inc. & Studio Makyu Co., Ltd.
Business partnership regarding the crowdfunding “Supporters of Biozipcode.”

Biozipcode, Inc. & YTT Medical Co., Ltd. & Tsuyuki Corporation
MoU on business financing.

KIYAN MEDICAL CO., Ltd. / KIYAN PHARMA Co., Ltd.

2024

KIYAN MEDICAL CO., Ltd. / KIYAN PHARMA Co., Ltd. & Biozipcode, Inc.
Business partnership for a cure for diabetes using 5‑ALA.

Mitsui Chemicals, Inc. & Shiga University of Medical Science & Biozipcode, Inc.
Tripartite joint research agreement.

Biozipcode, Inc. & Studio Makyu Co., Ltd. & Auring Ltd.
Business partnership for the issuance of the Global Development Token.

The Kotobuki Clinic

2025

The Kotobuki Clinic & Biozipcode, Inc.
Joint research on diabetes treatment using 5‑ALA.

Biozipcode, Inc. & Palau Sambas Development Inc.
Memorandum of Understanding (MoU) on a diabetes clinical trial and a cure for diabetes in Palau.
Outsourcing agreement for related services in clinical research on diabetes biomarkers.

Diabetes Can Be Cured.

Looking for Partners

We are looking for partners and collaborators to grow with us. Whether in research, business, or community development, your participation can help accelerate our mission.

Contact Us

Unlock the Cure Economy.

Join the GDT ICO and shape the future of global health.